证券代码：688621 证券简称：阳光诺和 公告编号：2025-105 表决情况：9票同意，0票反对，0票弃权。 本议案尚需提交公司股东会审议。 第二届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"）于 2025年11月25日召开第二届董事会第二十七次会议。本次会议通知于2025年11 月21日以直接送达、传真与邮件方式发出，会议由董事长利虔先生召集和主持， 会议应出席董事9名，实际出席董事9名，会议的召集和召开符合《中华人民共和 国公司法》及《北京阳光诺和药物研究股份有限公司章程》等法律、行政法规、 部门规章、规范性文件的规定。 二、董事会会议审议情况 经与会董事认真审议，一致通过如下决议： （一）审议通过《关于转让控股孙公司股权暨募投项目转让的议案》 经审议，董事会同意公司全资子公司北京诺和德美医药技术有限公司（以下 简称"诺和德美"）与北京中健培联医学研究院（普通合伙）（以下简称"中健培联"） 签署 ...

企查查APP显示，近日，北京阿尔纳科技有限公司成立，注册资本1000万元，经营范围包含：人体基因 诊断与治疗技术开发；软件开发；人工智能基础软件开发等。企查查股权穿透显示，该公司由阳光诺和 （688621）全资持股。 （原标题：阳光诺和成立科技新公司，含AI软件开发业务） ...

Core Insights - The total margin balance of the STAR Market on November 21 reached 251.77 billion yuan, a decrease of 4.746 billion yuan from the previous trading day [1] - The financing balance amounted to 250.91 billion yuan, down by 4.711 billion yuan, while the securities lending balance was 0.865 billion yuan, a reduction of 0.035 billion yuan [1] Individual Stock Performance - On November 21, 217 stocks in the STAR Market experienced net financing inflows, with 8 stocks having net inflow amounts exceeding 20 million yuan [1] - Dekoli topped the list with a net financing inflow of 1.56 billion yuan, followed by Aikesaibo, Yuanjie Technology, Haibosi Chuang, Yangguang Nuohuo, and Ruilian New Materials [1]

Core Insights - On November 21, Sunshine Nuohuo's stock rose by 4.47%, with a trading volume of 530 million yuan [1] - The company reported a financing buy-in of 93.76 million yuan and a net financing buy of 30.38 million yuan on the same day [1][2] - As of September 30, 2025, Sunshine Nuohuo's revenue decreased by 6.65% year-on-year to 856 million yuan, and net profit fell by 21.38% to 163 million yuan [2] Financing and Margin Trading - On November 21, the total financing and margin trading balance for Sunshine Nuohuo reached 626 million yuan, accounting for 9.13% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of activity [1] - There were no shares sold or repaid in the margin trading segment on the same day, with a balance of 0 yuan [1] Shareholder and Dividend Information - As of September 30, 2025, the number of shareholders increased by 6.76% to 9,204, while the average number of circulating shares per person decreased by 6.33% [2][3] - The company has distributed a total of 105 million yuan in dividends since its A-share listing, with 84.29 million yuan distributed over the past three years [3] - Notable changes in institutional holdings include a reduction in shares held by the sixth-largest shareholder and the entry of a new shareholder, Hong Kong Central Clearing Limited [3]

Core Viewpoint - The company is currently involved in a significant legal dispute with Hunan Hengsheng Pharmaceutical Co., Ltd., with ongoing appeals and potential financial implications for the company [2][3][5]. Summary by Sections Legal Proceedings - The case is in the second instance of litigation, which has been filed but not yet heard [2]. - The company is both the appellant and the appellee in this case, having filed a counterclaim against Hengsheng Pharmaceutical [2][3]. Financial Implications - The original claim amount is 20 million yuan, with a counterclaim of approximately 7.41 million yuan, and the first-instance judgment amounting to about 2.4 million yuan [2]. - The company has proactively made full provisions for bad debts related to accounts receivable and contract assets, indicating that the lawsuit will not negatively impact current or future profits [2][7]. Recent Developments - Following the first-instance judgment, the company has submitted an appeal to the Hunan High People's Court, seeking to overturn the initial ruling and support its counterclaims [5]. - Hengsheng Pharmaceutical has also filed an appeal, requesting the enforcement of a technical development contract and an increase in the compensation amount [6].

Core Viewpoint - The company is currently involved in a significant legal dispute with Hunan Hengsheng Pharmaceutical Co., Ltd, with the case now in the second instance of litigation, having been filed but not yet heard in court [2][5]. Summary by Sections Litigation Status - The case is in the second instance, which has been filed but not yet heard in court [2]. - The company is both the appellant and the appellee in this case, having been the defendant in the first instance and now filing a counterclaim [2]. Financial Implications - The amount involved in the original lawsuit is 20,000,000.00 yuan, while the counterclaim amounts to 7,407,283.51 yuan, and the first-instance judgment awarded 2,403,230.253 yuan [2]. - The company has fully provisioned for bad debts related to accounts receivable and contract assets from Hengsheng Pharmaceutical, indicating that the lawsuit will not negatively impact the company's current or future profits [2][7]. Legal Actions Taken - The company has filed an appeal against the first-instance judgment, seeking to overturn specific parts of the ruling and requesting that the court dismiss the plaintiff's claims while supporting the company's counterclaims [5]. - Hengsheng Pharmaceutical has also filed an appeal, requesting the enforcement of a technical development contract and seeking to amend the compensation awarded in the first-instance judgment [6][7].

Group 1 - Central Plaza received a warning letter from Jiangsu Securities Regulatory Commission due to failure to timely disclose significant litigation progress and accounting treatment, affecting the accuracy of the 2025 semi-annual report [4] - Jiaron Technology announced a stock suspension as it plans a major asset restructuring through share issuance and fundraising, with the suspension expected to last no more than 10 trading days [5] - Maiwei Co. is undergoing a debt restructuring involving accounts receivable totaling 371 million yuan, with an estimated loss of 85.465 million yuan, aimed at accelerating cash flow recovery and reducing receivables risk [6] Group 2 - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, having previously used 575 million yuan for similar purposes [7] - Huyou Pharmaceutical's HYP-6589 tablet clinical trial application for treating advanced non-small cell lung cancer has been accepted by the National Medical Products Administration [8] - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 740.73 thousand yuan [9] Group 3 - Guolian Aquatic received a warning letter from Guangdong Securities Regulatory Commission for non-operating fund occupation by its controlling shareholder, with a total borrowing of 7.8 million yuan [10] - Renfu Pharmaceutical's application for the marketing authorization of Dexmethylphenidate capsules has been accepted, targeting ADHD treatment [11] - Jindi Co. signed a strategic cooperation letter with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies [12] Group 4 - Yuyuan Co. repurchased 1 million A-shares for a total payment of approximately 5.386 million yuan, as part of a broader repurchase plan of 200-300 million yuan [13] - Yuheng Pharmaceutical's executives increased their holdings by 1.12% through a judicial auction, acquiring 25 million shares [14] - Zhonghuan Co. shareholders plan to reduce their holdings by 1.02% and 0.24% respectively, citing personal funding needs [15] Group 5 - Huibo Co. won a contract for the Iraq NaftKhana oilfield restoration project worth approximately 1.596 billion yuan, expected to significantly impact 2026-2027 performance [17] - Dajin Heavy Industry's subsidiary signed a contract for a European offshore wind farm project valued at approximately 1.339 billion yuan, representing 35.41% of the company's 2024 audited revenue [18]

Regulatory Actions - Haosai is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal and the investigation will not significantly impact management [2] - Central Plaza and its executives received a warning letter from the Jiangsu Securities Regulatory Bureau for failing to timely disclose significant litigation progress, which led to inaccurate financial reporting [3] - Guolian Aquatic received a warning letter from the Guangdong Securities Regulatory Bureau for non-operating fund occupation by its controlling shareholder, which was not disclosed in a timely manner [9] Corporate Actions - Jiarong Technology is planning a major asset restructuring and has suspended trading of its shares, expected to last no more than 10 trading days [4] - Maiwei Co. announced a debt restructuring totaling 371 million yuan, with an expected loss of 85.465 million yuan, aimed at improving cash flow and reducing receivables risk [5] - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, with a total of 575 million yuan already invested in such products [6] Legal Matters - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 7.4073 million yuan [8] Product Development - Huyou Pharmaceutical's HYP-6589 tablet has received acceptance for clinical trial applications for treating advanced non-small cell lung cancer [7] - Renfu Pharmaceutical's application for the marketing license of a new ADHD treatment has been accepted, with no similar products currently available in the domestic market [10] Strategic Partnerships - Jindi Co. signed a strategic cooperation letter of intent with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies and key components [11] Share Buybacks and Holdings - Yuyuan Co. has repurchased 1 million A-shares for a total of approximately 5.3864 million yuan as part of a buyback plan [12] - Yuheng Pharmaceutical's executives increased their holdings by 1.12%, acquiring a total of 25 million shares [13] Major Contracts - Huayou Huibo has been awarded a contract worth 225 million USD for the Iraq NaftKhana oilfield project, which is expected to significantly impact future earnings [16] - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, representing 35.41% of the company's expected annual revenue [17]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-103 北京阳光诺和药物研究股份有限公司 关于公司诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为切实维护公司和股东的利益，针对上述一审判决结果，公司向湖南省高级 人民法院提交《民事上诉状》，上诉状的主要内容如下： （1）依法撤销一审判决第一项、第二项、第四项，改判驳回被上诉人的全 部诉讼请求、支持上诉人的全部反诉请求；或将本案发回一审法院重审； 案件所处的诉讼阶段：二审已立案，尚未开庭 上市公司所处的当事人地位：上诉人及被上诉人（一审被告及反诉原告） 涉案金额：原起诉状中涉案金额为 20,000,000.00 元；反诉金额为 7,407,283.51 元；一审判决金额为 2,403,230.253 元。 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对恒生制药应收账款和合同资产全额计提了坏账准备，因此该诉讼事项对公 司当期及期后利润不会构成负面影响。截至本公告日，本次诉讼二审尚未开庭审 理，最终执行 ...